Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate

Ryuta Uraki¹, Mutsumi Ito², Maki Kiso², Seiya Yamayoshi¹, Kiyoko Iwatsuki-Horimoto², Yuri Furusawa¹, Yuko Sakai-Tagawa², Masaki Imai¹, Michiko Koga³, Shinya Yamamoto⁴, Eisuke Adachi⁵, Makoto Saito³, Takeya Tsutsumi³, Amato Otani⁵, Tetsuhiro Kikuchi⁶, Hiroshi Yotsuyanagi³, Peter J Halfmann⁷, Andrew Pekosz⁸, Yoshihiro Kawaoka⁹

Affiliations

¹ Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
² Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
³ Division of Infectious Diseases, Advanced Clinical Research Center, University of Tokyo, Tokyo 108-8639, Japan; Department of Infectious Diseases and Applied Immunology, Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
⁴ Division of Infectious Diseases, Advanced Clinical Research Center, University of Tokyo, Tokyo 108-8639, Japan; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
⁵ Department of Infectious Diseases and Applied Immunology, Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
⁶ Clinic of Nihon Sumo Kyokai, Tokyo, Japan.
⁷ Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
⁸ Department of Microbiology and Immunology, School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
⁹ Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; Pandemic Preparedness, Infection and Advanced Research Center, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: yoshihiro.kawaoka@wisc.edu.

PMID: 36773622
PMCID: PMC9908083
DOI: 10.1016/S1473-3099(23)00070-1

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate

Ryuta Uraki et al. Lancet Infect Dis. 2023 Apr.

. 2023 Apr;23(4):402-403.

doi: 10.1016/S1473-3099(23)00070-1. Epub 2023 Feb 8.

Authors

Affiliations

¹ Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
² Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
³ Division of Infectious Diseases, Advanced Clinical Research Center, University of Tokyo, Tokyo 108-8639, Japan; Department of Infectious Diseases and Applied Immunology, Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
⁴ Division of Infectious Diseases, Advanced Clinical Research Center, University of Tokyo, Tokyo 108-8639, Japan; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
⁵ Department of Infectious Diseases and Applied Immunology, Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
⁶ Clinic of Nihon Sumo Kyokai, Tokyo, Japan.
⁷ Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
⁸ Department of Microbiology and Immunology, School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
⁹ Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; Pandemic Preparedness, Infection and Advanced Research Center, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: yoshihiro.kawaoka@wisc.edu.

PMID: 36773622
PMCID: PMC9908083
DOI: 10.1016/S1473-3099(23)00070-1

No abstract available

PubMed Disclaimer

Conflict of interest statement

YK declares support from grants from the Center for Research on Influenza Pathogenesis and Transmission (75N93021C00014), the National Institute of Allergy and Infectious Diseases, a research programme on emerging and re-emerging infectious diseases (JP21fk0108552 and JP21fk0108615), a project promoting support for drug discovery (JP21nf0101632), the Japan Program for Infectious Diseases Research and Infrastructure (JP22wm0125002), and the Japan Initiative for World-leading Vaccine Research and Development Centers (JP223fa627001) from the the Japan Agency for Medical Research and Development. YK has received unrelated funding from Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns Laboratories, Shionogi, Otsuka Pharmaceutical, KM Biologics, Kyoritsu Seiyaku, Shinya, and Fuji Rebio. TK is employed by Nihon Sumo Kyokai. All other authors declare no competing interests.

References

1. Imai M, Ito M, Kiso M, et al. Efficacy of antiviral agents against omicron subvariants BQ.1.1 and XBB. N Engl J Med. 2023;388:89–91. - PMC - PubMed
1. Uraki R, Ito M, Furusawa Y, et al. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect Dis. 2023;23:30–32. - PMC - PubMed
1. Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186:279–286. - PMC - PubMed
1. Davis-Gardner ME, Lai L, Wali B, et al. Neutralization against BA.2.75·2, BQ.1.1, and XBB from mRNA bivalent booster. N Engl J Med. 2023;388:183–185. - PMC - PubMed
1. Zhang X, Chen L-L, Lp JD, et al. Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines. Lancet Microbe. 2022 doi: 10.1016/S2666-5247(22)00335-4. published online Dec 6. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate

Affiliations

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate

Authors

Affiliations

Conflict of interest statement

References

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical